Icahn To Cornelius: “I Don’t Understand”
This article was originally published in The Pink Sheet Daily
Executive Summary
ImClone chairman scolds Bristol-Myers Squibb CEO in latest correspondence.
You may also be interested in...
“Unhappy” BMS To ImClone: Erbitux, Follow-on Still Ours
After the rejected buyout offer, rights to compounds won't be modified.
Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder
Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.